Published in Acta Neuropathol on May 28, 2008
TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol (2010) 2.81
Primary progressive aphasia: clinicopathological correlations. Nat Rev Neurol (2010) 2.19
Novel CSF biomarkers for frontotemporal lobar degenerations. Neurology (2010) 1.89
Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: the TDP-43 diseases. J Neurol (2009) 1.85
Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: a spectrum of TDP-43 proteinopathies. Neuropathology (2010) 1.53
Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathol (2010) 1.38
Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. Arch Neurol (2010) 1.29
Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol (2014) 1.21
The human frontal lobes and frontal network systems: an evolutionary, clinical, and treatment perspective. ISRN Neurol (2013) 1.09
The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia. Curr Opin Neurol (2008) 1.05
Transactivation response DNA-binding protein 43 microvasculopathy in frontotemporal degeneration and familial Lewy body disease. J Neuropathol Exp Neurol (2009) 1.01
On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia. Prog Neurobiol (2011) 0.95
Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease. Front Aging Neurosci (2013) 0.94
Biomarkers in frontotemporal lobar degenerations--progress and challenges. Prog Neurobiol (2011) 0.91
Amyotrophic lateral sclerosis: update and new developments. Degener Neurol Neuromuscul Dis (2012) 0.91
Dual vulnerability of TDP-43 to calpain and caspase-3 proteolysis after neurotoxic conditions and traumatic brain injury. J Cereb Blood Flow Metab (2014) 0.87
TAR DNA-binding protein-43 in amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer disease. Acta Neuropathol (2008) 0.84
TMEM106B and APOE polymorphisms interact to confer risk for late-onset Alzheimer's disease in Han Chinese. J Neural Transm (Vienna) (2013) 0.83
Plasma phosphorylated-TDP-43 protein levels correlate with brain pathology in frontotemporal lobar degeneration. Acta Neuropathol (2009) 0.81
Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia. Expert Opin Ther Targets (2008) 0.80
The potential of pathological protein fragmentation in blood-based biomarker development for dementia - with emphasis on Alzheimer's disease. Front Neurol (2015) 0.79
Biomarkers to identify the pathological basis for frontotemporal lobar degeneration. J Mol Neurosci (2011) 0.78
Recent insights into the involvement of progranulin in frontotemporal dementia. Curr Neuropharmacol (2011) 0.76
Therapeutic and diagnostic challenges for frontotemporal dementia. Front Aging Neurosci (2014) 0.76
Biomarkers in frontotemporal lobar degeneration. Curr Opin Neurol (2010) 0.76
TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies. Acta Neuropathol Commun (2015) 0.75
Biomarkers in the primary progressive aphasias. Aphasiology (2014) 0.75
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology (1998) 26.77
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature (2006) 11.59
TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun (2006) 10.69
Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature (2006) 9.31
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10
Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol (2007) 6.58
TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol (2007) 5.98
Frontotemporal dementia: clinicopathological correlations. Ann Neurol (2006) 5.14
TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol (2007) 5.02
Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. Acta Neuropathol (2006) 4.24
Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology (2004) 3.94
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol (2007) 3.55
Structural diversity and functional implications of the eukaryotic TDP gene family. Genomics (2004) 3.51
Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. Acta Neuropathol (2007) 3.44
Frontotemporal dementia. Lancet Neurol (2005) 2.96
The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. Brain (2006) 2.52
Frontotemporal lobar degeneration with motor neuron disease-type inclusions predominates in 76 cases of frontotemporal degeneration. Acta Neuropathol (2004) 2.41
Nuclear factor TDP-43 binds to the polymorphic TG repeats in CFTR intron 8 and causes skipping of exon 9: a functional link with disease penetrance. Am J Hum Genet (2004) 2.35
TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. Brain (2007) 2.25
TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathol (2007) 2.01
Progranulin gene mutations associated with frontotemporal dementia and progressive non-fluent aphasia. Brain (2006) 2.00
Prevalence and cognitive performances of clinical dementia rating 0.5 and mild cognitive impairment in Japan. The Tajiri project. Alzheimer Dis Assoc Disord (2004) 1.84
Prevalence of mild cognitive impairment: a population-based study in elderly subjects. Acta Neurol Scand (2002) 1.75
Histopathological changes underlying frontotemporal lobar degeneration with clinicopathological correlation. Acta Neuropathol (2005) 1.55
Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study. Brain (2006) 1.51
Mutations in progranulin explain atypical phenotypes with variants in MAPT. Brain (2006) 1.43
Neuropathologic, biochemical, and molecular characterization of the frontotemporal dementias. J Neuropathol Exp Neurol (2005) 1.18
Cathepsin D exon 2 polymorphism associated with general intelligence in a healthy older population. Mol Psychiatry (2003) 1.08
A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron (2011) 18.73
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature (2006) 11.59
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet (2006) 4.80
Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol (2009) 4.73
Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol (2008) 4.73
Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. Acta Neuropathol (2006) 4.24
A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol (2011) 4.15
Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. Acta Neuropathol (2007) 3.44
Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain (2012) 3.43
Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J (2006) 2.96
Prion-like spreading of pathological α-synuclein in brain. Brain (2013) 2.92
Computer-delivered interventions for alcohol and tobacco use: a meta-analysis. Addiction (2010) 2.77
Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative. Lancet Neurol (2007) 2.72
Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J (2003) 2.64
Frontotemporal lobar degeneration: clinical and pathological relationships. Acta Neuropathol (2007) 2.33
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol (2013) 2.32
FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol (2010) 2.30
Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun (2006) 2.27
Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol (2011) 2.17
Frontotemporal dementia. Br J Psychiatry (2002) 1.95
High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J (2010) 1.91
Distinct patterns of olfactory impairment in Alzheimer's disease, semantic dementia, frontotemporal dementia, and corticobasal degeneration. Neuropsychologia (2006) 1.80
Estrogen modulates cutaneous wound healing by downregulating macrophage migration inhibitory factor. J Clin Invest (2003) 1.77
A family with tau-negative frontotemporal dementia and neuronal intranuclear inclusions linked to chromosome 17. Brain (2006) 1.75
The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships. Brain (2011) 1.70
Cognitive phenotypes in Alzheimer's disease and genetic risk. Cortex (2007) 1.62
Crime, fear of crime, environment, and mental health and wellbeing: mapping review of theories and causal pathways. Health Place (2012) 1.58
Dementia lacking distinctive histology (DLDH) revisited. Acta Neuropathol (2006) 1.58
Histopathological changes underlying frontotemporal lobar degeneration with clinicopathological correlation. Acta Neuropathol (2005) 1.55
Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study. Brain (2006) 1.51
Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep (2013) 1.49
Psychiatric disorders in preclinical Huntington's disease. J Neurol Neurosurg Psychiatry (2006) 1.48
Mutations in progranulin explain atypical phenotypes with variants in MAPT. Brain (2006) 1.43
Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain (2009) 1.42
CLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/collagen type XXV. EMBO J (2002) 1.41
Dilatation of the Virchow-Robin space is a sensitive indicator of cerebral microvascular disease: study in elderly patients with dementia. AJNR Am J Neuroradiol (2005) 1.40
Analysis of the hexanucleotide repeat in C9ORF72 in Alzheimer's disease. Neurobiol Aging (2012) 1.33
TDP-43 pathological changes in early onset familial and sporadic Alzheimer's disease, late onset Alzheimer's disease and Down's syndrome: association with age, hippocampal sclerosis and clinical phenotype. Acta Neuropathol (2011) 1.32
Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathol Commun (2013) 1.32
Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol (2008) 1.30
Frontotemporal lobar degeneration genome wide association study replication confirms a risk locus shared with amyotrophic lateral sclerosis. Neurobiol Aging (2011) 1.27
Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia. J Biol Chem (2005) 1.26
An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies. Acta Neuropathol (2006) 1.24
Parietal lobe deficits in frontotemporal lobar degeneration caused by a mutation in the progranulin gene. Arch Neurol (2008) 1.20
TDP-43 gene analysis in frontotemporal lobar degeneration. Neurosci Lett (2007) 1.20
Pathological correlates of frontotemporal lobar degeneration in the elderly. Acta Neuropathol (2010) 1.19
Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Free Radic Biol Med (2002) 1.19
The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene. Acta Neuropathol (2011) 1.18
Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J (2011) 1.16
Cancer survivors' views of work 3 years post diagnosis: a UK perspective. Eur J Oncol Nurs (2008) 1.16
Variability in cognitive presentation of Alzheimer's disease. Cortex (2007) 1.15
Behavior in Huntington's disease: dissociating cognition-based and mood-based changes. J Neuropsychiatry Clin Neurosci (2002) 1.13